AstraZeneca Stock

AstraZeneca PEG

The PEG Ratio (Price/Earnings-to-Growth) of AstraZeneca (AZN.L) as of Aug 18, 2026 is 0.63. In the previous year, PEG Ratio (Price/Earnings-to-Growth) was 0.92 — a change of -31.20% (lower).

PEG

0.63

YoY

-31.20%

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of AstraZeneca is 2026 0.63 . PEG Ratio (Price/Earnings-to-Growth) of AstraZeneca was 2025 0.92 . It decreases by -31.20% lower compared to the previous year.
Access this data via the Eulerpool API

AstraZeneca Stock analysis

What does AstraZeneca do? AstraZeneca PLC is a globally operating pharmaceutical company with its headquarters in England. The company was founded in 1999 through the merger of the Swedish company Astra AB and the British Zeneca Group PLC. Today, AstraZeneca employs more than 70,000 people and operates in over 100 countries. AstraZeneca specializes in the development, manufacturing, and marketing of pharmaceutical products. The company focuses primarily on oncology, cardiovascular and metabolic diseases, respiratory diseases, and autoimmune diseases. AstraZeneca is divided into various business segments. The oncology segment is a major focus of the company. Here, medications for various types of cancer are developed and manufactured. One particularly well-known product is the breast cancer medication Tamoxifen. In the cardiovascular and metabolic diseases segment, AstraZeneca offers various medications for heart and circulatory diseases as well as diabetes. One of the most well-known medications is Crestor, which is used to lower cholesterol levels. Another important area for AstraZeneca is respiratory diseases. Medications for the treatment of asthma and chronic obstructive pulmonary disease (COPD) are developed and manufactured here. The medication Pulmicort is particularly well-known among asthma patients. Finally, AstraZeneca is also active in the field of autoimmune diseases. Medications against lupus erythematosus and rheumatoid arthritis are developed and manufactured here. AstraZeneca strives to improve healthcare worldwide through research and development of new medications. The company works closely with universities and research institutions and invests billions of dollars annually in research and development. AstraZeneca also pursues a sustainable business strategy and emphasizes acting environmentally and socially responsibly. The company is committed to reducing CO2 emissions and minimizing waste production. Over the years, AstraZeneca has received numerous awards and prizes, including the Sunday Times Innovation Award of the Decade, the Fierce Biotech Award for the medication Tagrisso, and the Prix Galien USA Award for Crestor. AstraZeneca aims to develop innovative medications that improve the lives of patients and advance healthcare worldwide. The company believes in a sustainable business strategy and actively promotes environmental and social responsibility. AstraZeneca will remain an important player in the global pharmaceutical industry in the future. AstraZeneca is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AstraZeneca stock

PEG Ratio (Price/Earnings-to-Growth) of AstraZeneca is 0.63 in 2026.

PEG Ratio (Price/Earnings-to-Growth) of AstraZeneca changed from 0.92 to 0.63, representing a -31.20% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) AstraZeneca since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s AstraZeneca with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — AstraZeneca

All Key Metrics — AstraZeneca